Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Antibody Shows Promise for Developing Hantavirus Treatment

by Global Biodefense Staff
March 22, 2022
Antibody Shows Promise for Developing Hantavirus Treatment

This transmission electron microscopic (TEM) image revealed the ultrastructural appearance of a number of Sin Nombre virus (SNV) particles, or virions. SNV is a species of the genus Hantavirus, the primary etiologic agent of hantavirus cardiopulmonary syndrome (HCPS), also referred to as hantavirus pulmonary syndrome (HPS). Credit: M.L. Martin and E.L. Palmer / CDC

An international research team discovered the first human antibody to effectively neutralize two types of hantaviruses in animal models, according to a study published online Mar. 16 in Science Translational Medicine.

Based on their initial results, the antibody appears to be a promising candidate for developing a “pan-hantavirus” therapy to protect against outbreaks caused by multiple types of known or emerging hantaviruses.   

Collectively, hantaviruses cause about 50,000 severe and often fatal infections worldwide in people each year. While humans are typically infected by contact with rodents, the viruses also can be transmitted by direct person-to-person contact. No approved therapies are currently available for treating hantavirus infection.

Rodent-borne hantaviruses are grouped into two distinct viral families, commonly called “Old World” and “New World” hantaviruses, and cause two types of disease. Hemorrhagic fever with renal syndrome (HFRS) is caused by Old World viruses found mostly in Europe and Asia, while New World viruses cause hantavirus cardiopulmonary syndrome (HCPS) and are typically found in North and South America.

Hantavirus particles display a characteristic square surface “lattice” made up of building blocks that contain the envelope glycoproteins Gn and Gc. These glycoproteins, which are the sole targets of neutralizing antibodies, control the virus’s ability to enter cells. Figure shows a schematic representation of the glycoproteins and how they are organized within the virus particle (top, front view; bottom, side view). Key: Gn, green; Gn capping loop, purple; Gc domain I, red; Gc domain II, yellow; Gc domain III, blue; Gc fusion loops, orange. Approximate position of the viral membrane is indicated with a black line. Credit: USAMRIID

In this paper, scientists describe isolating several human monoclonal antibodies, or mAbs, from a patient in Sweden who survived infection with Puumala virus, which causes HFRS in humans. Through initial screening in cell culture, the team identified several mAbs that effectively neutralized both Old World and New World hantaviruses.

Next, the researchers tested a mAb that looked especially promising in two different animal models. They challenged hamsters and voles with Puumala (Old World) virus and Andes (New World) virus, and found that this single antibody afforded broad protection to both groups.

“This is the first monoclonal antibody to demonstrate cross-protective efficacy against divergent Old and New World hantaviruses,” said Andrew S. Herbert, Ph.D., branch chief for viral immunology at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Herbert served as co-senior author of the paper and directed the Andes virus challenge studies at the Institute.

According to the authors, hantavirus outbreaks in Sweden, Argentina, and the United States over the past two decades highlight the public health risks posted by these viruses. The frequency of these and other emerging disease outbreaks is expected to grow in concert with animal habitat loss and climate change.

“The lack of FDA-approved or emergency use-authorized vaccines and therapeutics represents a critical gap in our preparedness for a public health emergency caused by a large hantavirus outbreak,” they conclude.

Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Science Translational Medicine, 16 March 2022.

Summary: Rodent-borne orthohantaviruses are globally distributed zoonotic viruses causing hantavirus cardiopulmonary syndrome (HCPS) or hemorrhagic fever with renal syndrome (HFRS). Currently, no FDA-approved vaccines or antiviral therapies exist to prevent or treat severe and potentially fatal disease caused by emerging hantaviruses. Mittler et al. describe the isolation of human monoclonal antibodies (mAbs) against the spike protein complex of the hantavirus Puumala virus (PUUV) from PUUV-experienced donors recovering from HFRS. The panel of 135 mAbs displayed varying cross-reactivity and neutralizing activity against viruses from different hantavirus clades and targeted distinct parts of the viral spike. The mAb ADI-42898 blocked viral entry by seven different hantaviruses and protected Syrian hamsters challenged with the HCPS-causing Andes virus or bank voles challenged with the HFRS-causing PUUV. These findings suggest that mAbs may have utility as therapeutics for treating hantavirus disease.

Sources: USAMRIID, Science Translational Medicine

Tags: Editor PickHantavirusNeglected Tropical DiseasesTherapeutic AntibodiesUSAMRIID

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy